MDX-1401
Phase 1Completed 0 watching 0 views this week๐ค Quiet
32
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hodgkin's Lymphomas
Conditions
Hodgkin's Lymphomas
Trial Timeline
Feb 1, 2008 โ Jan 1, 2010
NCT ID
NCT00634452About MDX-1401
MDX-1401 is a phase 1 stage product being developed by Bristol Myers Squibb for Hodgkin's Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00634452. Target conditions include Hodgkin's Lymphomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00634452 | Phase 1 | Completed |
Competing Products
20 competing products in Hodgkin's Lymphomas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Nivolumab + Brentuximab vedotin | Ono Pharmaceutical | Phase 3 | 77 |
| R-mabHDI and ABVD + ABVD | Eli Lilly | Phase 3 | 77 |
| Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| R-mabHD + ABVD | Eli Lilly | Phase 2 | 52 |
| LY317615 | Eli Lilly | Phase 2 | 52 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 33 |
| Bortezomib + Rituximab + Rituximab | Johnson & Johnson | Phase 3 | 77 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR1459 ๏ผYY-20394 + SHR1459 ๏ผYY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 33 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 33 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 33 |